533 An open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors

• Pan Zheng,
• Kun He

Affiliations

Pan Zheng

Division of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA

Kun He

5 Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China